Diana Langworthy: New Episode – Solving the DOAC vs. Warfarin Mystery in Cirrhosis
Diana Langworthy, Associate Professor at University of Minnesota College of Pharmacy, shared a post on LinkedIn:
“New episode going live tomorrow, Tuesday June 30th, on What’s It Worth?
S4E7 – The Cirrhosis Paradox: Solving the DOAC vs. Warfarin Mystery in Liver Disease
Join me and my co-hosts, Dr. Erin E Pauling, (ambulatory care and cardiology specialist from Binghamton University) and recent U of MN grad, Dr. Caleb Nelson-Lange.
In this episode, we dig into a systematic review and meta-analysis comparing DOACs vs. warfarin in patients with atrial fibrillation and liver disease, including cirrhosis.
We talk through:
Why anticoagulation decisions in liver disease are so nuanced
What the evidence suggests about DOAC safety and effectiveness
How to think about agent selection, especially apixaban vs. rivaroxaban
Why observational data can be helpful, but still leaves important clinical gaps
And with this episode, there is a patient-facing companion episode:
S4E7.5 – AFib, Blood Thinners, and Liver Disease: Questions to Ask Your Doctor
This short What’s It Worth? For Everyone episode is designed for patients and families navigating AFib, blood thinners, liver disease, and cirrhosis.
It explains the topic in plain language and ends with practical questions patients can bring to their healthcare team.
For healthcare professionals: listen to the full episode for the evidence deep dive, and consider sharing the companion episode with patients or caregivers who want a clearer starting point for the conversation.”
Stay updated with Hemostasis Today.
-
Jun 30, 2026, 05:20Jenny Amphlett: A Decade of Excellence in Anticoagulation Care
-
Jun 30, 2026, 05:06Brian Haddigan: Beyond Stent Design – The Importance of Blood Compatibility
-
Jun 30, 2026, 04:47Kaihang Wang: Portal Vein Thrombosis After Pediatric Liver Transplantation
-
Jun 30, 2026, 04:12Maia Meier: Driving Change for Women and Girls with Bleeding Disorders
-
Jun 30, 2026, 03:19Wolfgang Miesbach: Weight-Bearing Lunge Test for Ankle Assessment in Haemophilia?
-
Jun 30, 2026, 03:06Salvatore Brugaletta: Is Twelve Months of DAPT Still Too Long After ACS?
-
Jun 30, 2026, 02:55Edward Lee Carter: How A Landmark Stewardship Shift Reduced Unnecessary Antiplatelet Use Across VISN 8
-
Jun 30, 2026, 02:43Nicolas Gendron: More than a Research Fellowship – Leaving the Wagner Lab
-
Jun 30, 2026, 02:29Wolfgang Miesbach: Can We ‘Pre‑Tame’ the Immune System to Unlock Better AAV8 FVIII Expression?